1
|
Michels S, Massutí B, Vasyliv I, Stratmann J, Frank J, Adams A, Felip E, Grohé C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer RN, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, Provencio M, Merkelbach-Bruse S, Hellmich M, Sebastian M, Büttner R, Persigehl T, Rosell R, Wolf J. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial. ESMO Open 2024; 9:102237. [PMID: 38350336 PMCID: PMC10937203 DOI: 10.1016/j.esmoop.2024.102237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 12/12/2023] [Accepted: 01/07/2024] [Indexed: 02/15/2024] Open
Abstract
BACKGROUND In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the final analysis of OS, systemic and intracranial activity, and the impact of co-occurring aberrations. MATERIALS AND METHODS EUCROSS was a prospective, single-arm, phase II trial. The primary endpoint was best overall response rate (ORR) using RECIST 1.1. Secondary and exploratory endpoints were progression-free survival (PFS), OS, and efficacy in pre-defined subgroups. RESULTS Median OS of the intention-to-treat population (N = 34) was 54.8 months [95% confidence interval (CI) 20.3 months-not reached (NR); median follow-up 81.4 months] and median all-cause PFS of the response-evaluable population (N = 30) was 19.4 months (95% CI 10.1-32.2 months). Time on treatment was significantly correlated with OS (R = 0.82; P < 0.0001). Patients with co-occurring TP53 aberrations (28%) had a significantly shorter OS [hazard ratio (HR) 11; 95% CI 2.0-56.0; P = 0.006] and all-cause PFS (HR 4.2; 95% CI 1.2-15; P = 0.025). Patients with central nervous system (CNS) involvement at baseline (N = 6; 20%) had a numerically shorter median OS and all-cause PFS. Median intracranial PFS was 32.2 months (95% CI 23.7 months-NR) and the rate of isolated CNS progression was 24%. CONCLUSIONS Our final analysis proves the efficacy of crizotinib in ROS1-positive lung cancer, but also highlights the devastating impact of TP53 mutations on survival and treatment efficacy. Additionally, our data show that CNS disease control is durable and the risk of CNS progression while on crizotinib treatment is low.
Collapse
Affiliation(s)
- S Michels
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany.
| | - B Massutí
- Department for Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain
| | - I Vasyliv
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - J Stratmann
- Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main
| | - J Frank
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - A Adams
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - E Felip
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Grohé
- Department of Respiratory Medicine, ELK Berlin, Berlin, Germany
| | - D Rodriguez-Abreu
- Universidad de Las Palmas de Gran Canaria, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Gran Canaria, Spain
| | - H Bischoff
- Thoraxonkologie, Thoraxklinik, Heidelberg, Germany
| | - E Carcereny I Costa
- Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona and Badalona-Applied Research Group in Oncology (B-ARGO), Badalona
| | - J Corral
- Department for Medical Oncology, Clínica Universidad de Navarra, Madrid
| | - E Pereira
- Spanish Lung Cancer Group, Barcelona, Spain
| | - J Fassunke
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - R N Fischer
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - A Insa
- Hospital Clínico Universitario de Valencia, València, Spain
| | - S Koleczko
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - L Nogova
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Reck
- Department for Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research, Großhansdorf
| | - T Reutter
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany; Department of Oncology, Asklepios Clinic Altona, Hematology, Palliative Care and Rheumatology, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
| | - R Riedel
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - D Schaufler
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Scheffler
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| | - M Weisthoff
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - M Provencio
- Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid
| | - S Merkelbach-Bruse
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - M Hellmich
- Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - M Sebastian
- Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main
| | - R Büttner
- University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - T Persigehl
- University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
| | - R Rosell
- Germans Trias i Pujol Research Institute (IGTP), Badalona; Quiron Dexeus University Hospital, Institute of Oncology Rosell (IOR), Barcelona, Spain
| | - J Wolf
- Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany
| |
Collapse
|
2
|
Castelo-Branco L, Morgan G, Prelaj A, Scheffler M, Canhão H, Van Meerbeeck JP, Awada A. Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions. ESMO Open 2023; 8:100764. [PMID: 36640544 PMCID: PMC10024152 DOI: 10.1016/j.esmoop.2022.100764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 11/13/2022] [Accepted: 12/05/2022] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Immune checkpoint-inhibitors (ICIs) are changing outcomes in different cancer settings, notably for patients with non-small-cell lung cancer (NSCLC). There are, however, still important gaps of evidence for clinical practice when using these novel treatments. In this study, we assessed physicians' opinion and experience on challenges for clinical practice with ICIs monotherapy in NSCLC. METHODS A survey was conducted on experienced physicians treating patients with NSCLC with ICIs. Two rounds of pilot tests were carried out for validation among a group of experts. Topics under analysis were in relation to treatment of elderly populations, performance status, brain metastases, use of steroids or antibiotics, the effects of gut microbiome, autoimmune diseases, human immunodeficiency virus infection, solid organ transplants, use of anti-programmed cell death protein 1 versus anti-programmed death-ligand 1 drugs, atypical tumour responses, predictors of response, duration of treatment and a final open question on additional relevant challenges. RESULTS Two hundred and twenty-one answers were collected, including 106 (48%) valid answers from experts for final analysis (physicians who have treated at least 20 patients with NSCLC with ICIs). The vast majority agreed that the selected topics in this study are important challenges ahead and more evidence is needed. Moreover, predictors of response, treating brain metastasis, shorter duration of treatment, the effects of gut microbiome and concomitant use of steroids were voted the most important topics to be further addressed in prospective clinical research. CONCLUSIONS This survey contributed to understanding which are the main challenges for clinical practice with ICIs monotherapy in NSCLC. It can also contribute to guide further clinical research, considering the opinions and experience of those who regularly treat NSCLC patients with ICIs.
Collapse
Affiliation(s)
- L Castelo-Branco
- NOVA National School of Public Health, NOVA University, Lisbon, Portugal.
| | - G Morgan
- Skåne University Hospital, Division of Medical and Radiation Oncology, Lund, Sweden
| | - A Prelaj
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy
| | - M Scheffler
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Cologne, Germany
| | - H Canhão
- EPIDOC Unit, Comprehensive Health Research Center (CHRC), NOVA Medical School, NOVA University, Lisbon; Centro Hospitalar Universitario Lisboa Central, Lisbon, Portugal
| | | | - A Awada
- Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
3
|
Glaser M, von Levetzow C, Michels S, Nogova L, Katzenmeier M, Wömpner C, Schmitz J, Bitter E, Terjung I, Passmann E, Schaufler D, Eisert A, Fischer R, Riedel R, Hahne S, Merkelbach-Bruse S, Büttner R, Wolf J, Scheffler M. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Scheffler M, Dugan M, Saleh M, Koleczko S, Brägelmann J, Arolt C, Nogova L, Riedel R, Michels S, Eisert A, Fischer R, Scharpenseel H, Weber JP, Scheel A, Merkelbach-Bruse S, Büttner R, Lafleur F, Wild R, Catanzariti L, Hillmer A, Wolf J. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel A, Brägelmann J, Merkelbach-Bruse S, Wolf J, Büttner R, Lafleur F, Scheffler M, Catanzariti L, Hillmer A. EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Glaser M, von Levetzow C, Michels S, Nogova L, Katzenmeier M, Wömpner C, Schmitz J, Bitter E, Terjung I, Passmann E, Schaufler D, Eisert A, Fischer R, Riedel R, Weber JP, Hahne S, Merkelbach-Bruse S, Büttner R, Wolf J, Scheffler M. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Kron A, Scheffler M, Ihle M, Michels S, Süptitz J, Prang D, Jakobs F, Nogova L, Fischer R, Eisert A, Riedel R, Kron F, Hillmer A, Loges S, Merkelbach-Bruse S, Büttner R, Wolf J. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
8
|
Knight L, Pahud BA, Scheffler M, Euteneuer JC, Allen C, Ross J, Ali W, Meyer M, Purohit PJ, Zimmerman KO, Sullivan JE. Capacity Building in a New Clinical Trials Network through Inter-Network Collaboration. J Pediatr 2022; 240:5-8. [PMID: 33940019 PMCID: PMC9047255 DOI: 10.1016/j.jpeds.2021.04.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 04/27/2021] [Indexed: 01/03/2023]
Affiliation(s)
- Lisa Knight
- Division of Pediatric Endocrinology, Department of Pediatrics, University of South Carolina School of Medicine, Columbia, SC.
| | - Barbara A Pahud
- Division of Pediatric Infectious Disease, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO
| | - Margaret Scheffler
- Division of Pediatric Critical Care, Department of Pediatrics, Brown University Warren Alpert Medical School, Providence, RI
| | - Joshua C Euteneuer
- Division of Neonatology, Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE
| | - Christine Allen
- Division of Pediatric Critical Care, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | - Judith Ross
- Department of Pediatrics, Alfred I duPont Hospital for Children, Wilmington, DE
| | - Wail Ali
- Division of Pediatric Critical Care, Department of Pediatrics, West Virginia University, Morgantown, WV
| | - Marisa Meyer
- Division of Critical Care Medicine, Department of Pediatrics, Alfred I duPont Hospital for Children, Wilmington, DE
| | - Prashant J Purohit
- Division of Pediatric Critical Care, Department of Pediatrics, Kapi'olani Medical Center for Women and Children, Honolulu, HI
| | - Kanecia O Zimmerman
- Duke University Medical Center, Durham, NC and Duke Clinical Research Institute, Durham, NC
| | - Janice E Sullivan
- Division of Clinical and Translational Research, Department of Pediatrics, University of Louisville and Norton Children's Hospital, Louisville, KY
| |
Collapse
|
9
|
Riudavets Melia M, Auclin E, Aboubakar F, Ponce Aix S, Dal Maso A, Bluthgen V, Mielgo X, Mussat E, Reyes R, Benítez J, Lupinacci L, Duchemann B, de Giglio A, Bautista J, Audigier-Valette C, Scheffler M, Campayo M, Besse B, Planchard D, Mezquita L. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
10
|
Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open 2021; 6:100104. [PMID: 33838532 PMCID: PMC8038939 DOI: 10.1016/j.esmoop.2021.100104] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 02/28/2021] [Accepted: 03/03/2021] [Indexed: 11/26/2022] Open
Abstract
Background The COVID-19 pandemic has impacted all aspects of modern-day oncology, including how stakeholders communicate through social media. We surveyed oncology stakeholders in order to assess their attitudes pertaining to social media and how it has been affected during the pandemic. Materials and methods A 40-item survey was distributed to stakeholders from 8 July to 22 July 2020 and was promoted through the European Society for Medical Oncology (ESMO) and the OncoAlert Network. Results One thousand and seventy-six physicians and stakeholders took part in the survey. In total, 57.3% of respondents were medical oncologists, 50.6% aged <40 years, 50.8% of female gender and mostly practicing in Europe (51.5%). More than 90% of respondents considered social media a useful tool for distributing scientific information and for education. Most used social media to stay up to date on cancer care in general (62.5%) and cancer care during COVID-19 (61%) given the constant flow of information. Respondents also used social media to interact with other oncologists (78.8%) and with patients (34.4%). Overall, 61.1% of respondents were satisfied with the role that social media was playing during the COVID-19 pandemic. On the other hand, 41.1% of respondents reported trouble in discriminating between credible and less credible information and 30% stated social networks were a source of stress. For this reason, one-third of respondents reduced its use during the COVID-19 pandemic. Regarding meeting attendance, a total of 59.1% of responding physicians preferred in-person meetings to virtual ones, and 51.8% agreed that virtual meetings and social distancing could hamper effective collaboration. Conclusion Social media has a useful role in supporting cancer care and professional engagement in oncology. Although one-third of respondents reported reduced use of social media due to stress during the COVID-19 pandemic, the majority found social media useful to keep up to date and were satisfied with the role social media was playing during the pandemic. More than 90% of the 1076 respondents believed in the role of social media promoting scientific information and education. 41% of respondents had trouble discriminating between credible and less credible information on social media. 61% of respondents used social media to stay up to date with scientific information regarding cancer care and COVID-19. The flow of information on COVID-19 via social media was deemed useful for 49% of respondents but caused stress in 30%. 52% of respondents agreed that virtual meetings and social distancing could hamper effective collaboration.
Collapse
Affiliation(s)
- G Morgan
- Department of Medical and Radiation Oncology, Skane University Hospital, Lund, Sweden.
| | - M Tagliamento
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy; Department of Medical Oncology, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - M Lambertini
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - B Devnani
- Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - B Westphalen
- Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians University Munich, Munich, Germany
| | - R Dienstmann
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - A Calles
- Hospital General Universitario Gregorio Marañon, Madrid, Spain
| | - C Criscitiello
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Hematology and Oncology (DIPO), University of Milan, Milan, Italy
| | - A Curioni
- Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland
| | - A M Garcia
- Section of Medical Oncology, Dagupan Doctors Villaflor Memorial Hospital, Dagupan, Philippines
| | - A Lamarca
- Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - S Pilotto
- Section of Oncology, Department of Medicine, University of Verona Hospital Trust, Verona, Italy
| | - M Scheffler
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany
| | - M Strijbos
- Department of Medical Oncology, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Monash University, Eastern Health Clinical School, Box Hill, Australia
| | - R Wong
- Department of Medical Oncology, Eastern Health, Box Hill, Australia
| | - E de Azambuja
- Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB.), Brussels, Belgium
| | - S Peters
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University, Lausanne, Switzerland
| |
Collapse
|
11
|
Riedel R, Heydt C, Scheel A, Tumbrink H, Brägelmann J, Fassunke J, Nogova L, Michels S, Scheffler M, Fischer R, Koleczko S, Weber J, Westphal T, Abdulla D, Merkelbach-Bruse S, Sos M, Büttner R, Wolf J. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Mezquita L, Swalduz A, Auclin E, Carter M, Steendam C, Aldea M, Scheffler M, Corral J, Viteri S, Segui E, Barba A, Dubbink E, Planchard D, Vasseur D, Reyes R, Caramella C, Recondo G, Saintigny P, Blackhall F, Dingemans A, Besse B. P84.01 The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Rotow J, Patel J, Hanley M, Yu H, Goldman J, Nechustan H, Scheffler M, Awad M, Clifford S, Santucci A, Silva L, Tupper R, Oxnard G, Kherani J, Drilon A. FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.150] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Riudavets M, Mezquita L, Auclin E, Benitez J, Le Pechoux C, Majem M, Dempsey N, Lobefaro R, Nadal E, Amores A, Menis J, Tagliamento M, López-Castro R, Ponce S, Bosch-Barrera J, Aboubakar F, Mosquera J, Pilotto S, Reyes R, Mielgo X, Duchemann B, Mosteiro M, Mussat E, De Giglio A, Scheffler M, Campayo M, Botticella A, Naltet C, Lavaud P, Lopes G, Signorelli D, Garcia-Campelo R, Besse B, Planchard D. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Carneiro A, Amaral T, Brandao M, Scheffler M, Bol K, Ferrara R, Jalving M, Lo Russo G, Marquez-Rodas I, Matikas A, Mezquita L, Morgan G, Onesti C, Pilotto S, Saloustros E, Trapani D. LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
16
|
Christoph D, Rizzo F, Kambartel KO, Winke S, Panse J, Abdulla D, Scheffler M, Azeh I, Hoiczyk M, Turki A, Metzenmacher M. 1374P Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol 2019; 29:2068-2075. [PMID: 30165392 PMCID: PMC6225899 DOI: 10.1093/annonc/mdy333] [Citation(s) in RCA: 116] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Background We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders. Results Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001). Conclusions In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
Collapse
Affiliation(s)
- A Kron
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - C Alidousty
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - M Scheffler
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - S Merkelbach-Bruse
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - D Seidel
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; CECAD Cluster of Excellence, University of Cologne, Cologne, Germany
| | - R Riedel
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - M A Ihle
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - S Michels
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - L Nogova
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - J Fassunke
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - C Heydt
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - F Kron
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - F Ueckeroth
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - M Serke
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, Germany
| | - S Krüger
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Florence Nightingale Hospital, Düsseldorf, Germany
| | - C Grohe
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Evangelische Lungenklinik Berlin (Paul Gerhardt Diakonie), Berlin, Germany
| | - D Koschel
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Fachkrankenhaus Coswig, Coswig, Germany
| | - J Benedikter
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Klinikum Bogenhausen, Munich, Germany
| | - B Kaminsky
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Krankenhaus Bethanien, Solingen, Germany
| | - B Schaaf
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Center, Klinikum Dortmund GmbH, Dortmund, Germany
| | - J Braess
- Network Genomic Medicine, Cologne, Germany; Department of Oncology and Hematology, Krankenhaus Barmherzige Brueder, Regensburg, Germany
| | - M Sebastian
- Network Genomic Medicine, Cologne, Germany; Department of Oncology and Hematology, University Hospital Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, Germany
| | - K-O Kambartel
- Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Bethanien Hospital Moers-Lungenzentrum, Moers, Germany
| | - R Thomas
- Network Genomic Medicine, Cologne, Germany; Cologne Center for Genomics, University Hospital of Cologne, Cologne, Germany
| | - T Zander
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany
| | - A M Schultheis
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - R Büttner
- Network Genomic Medicine, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - J Wolf
- Network Genomic Medicine, Cologne, Germany; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln Bonn, Cologne, Germany.
| |
Collapse
|
18
|
Michels S, Massuti Sureda B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohe C, Rodríguez-Abreu D, Bischoff H, Carcereny Costa E, Corral Jaime J, Insa A, Reck M, Scheffler M, Karachaliou N, Merkelbach-Bruse S, Nogova L, Büttner R, Rosell R, Wolf J. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Scheffler M, Chanra T, Kron A, Koleczko S, Abdulla D, Ihle M, Holzem A, Riedel R, Michels S, Fischer R, Merkelbach-Bruse S, Büttner R, Nogova L, Wolf J. Genomic and clinical characterization of non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Fischer R, George J, Scheel A, Schlösser H, Vehreschild M, Abdulla D, Koleczko S, Michels S, Nogova L, Riedel R, Scheffler M, Maas L, Brossart P, Engel-Riedel W, Griesinger F, Grohé C, Kern J, Hermes B, Nachtkamp K, Panse J, Sebastian M, Lehmann M, Wiewrodt R, Buettner R, Thomas R, Wolf J. OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.492] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Abdulla D, Ruge M, Scheffler M, Nogova L, Koleczko S, Persigehl T, Grau S, Drzezga A, Kobe C, Buettner R, Galldiks N, Wolf J. Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Thrower JD, Pantazidis G, Scheffler M, Simonsen FDS, Jensen PA, Hornekær L. Laboratory evidence for the formation of hydrogenated fullerene molecules. Proc Int Astron Union 2019; 15:144-147. [PMID: 33072168 PMCID: PMC7116202 DOI: 10.1017/s1743921319007567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Experimental evidence for the formation of hydrogenated fullerene molecules is presented. Films of C60 were grown on a highly oriented pyrolytic graphite (substrate) and exposed to a beam of deuterium atoms. Thermal desorption combined with mass spectrometry was used to determine the deuterated fullerene products formed, revealing a maximum degree of deuteration corresponding to C60D36. Release of D2 from the deuterated C60 film occurs at a much higher temperature than for D-saturated graphite.
Collapse
Affiliation(s)
- J. D. Thrower
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
| | - G. Pantazidis
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
| | - M. Scheffler
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
| | - F. D. S Simonsen
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
| | - P. A. Jensen
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
| | - L. Hornekær
- Department of Physics & Astronomy, Aarhus University, 8000 Aarhus C, Denmark
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus C, Denmark
| |
Collapse
|
23
|
Nogova L, Malchers F, Hillmer A, Merkelbach-Bruse S, Pinto A, Woempner C, Riedel R, Scheffler M, Michels S, De Porre P, Santiago-Walker A, Fischer R, Abdulla D, Thomas R, Buettner R, Wolf J. FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Scheffler M, Frank R, Ihle M, Abdulla D, Koleczko S, Nogova L, Holzem A, Chanra T, Riedel R, Michels S, Fischer R, Kron A, Merkelbach-Bruse S, Buettner R, Wolf J. Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Tuttle C, Boto J, Martin S, Barnaure I, Korchi AM, Scheffler M, Vargas MI. Neuroimaging of acute and chronic unilateral and bilateral thalamic lesions. Insights Imaging 2019; 10:24. [PMID: 30796553 PMCID: PMC6386756 DOI: 10.1186/s13244-019-0700-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2018] [Accepted: 11/08/2018] [Indexed: 11/10/2022] Open
Abstract
The thalami are bilateral ovoid grey matter cerebral structures bordering the third ventricle on both sides, which participate in functions such as relaying of sensory and motor signals, regulation of consciousness, and alertness. Pathologies affecting the thalami can be of neoplastic, infectious, vascular, toxic, metabolic, or congenital origin.The purpose of this review is to provide a comprehensive approach to the thalamus focusing on its anatomy, the main pathologies affecting this structure and their radiological semiology on CT and MRI. We will also illustrate the importance of multimodal MR imaging (morphologic sequences, diffusion-weighted imaging, perfusion, spectroscopy) for the diagnosis and treatment of these conditions.
Collapse
Affiliation(s)
- C Tuttle
- Division of Radiology, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
| | - J Boto
- Division of Neuroradiology, DISIM, Faculty of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland
| | - S Martin
- Division of Radiology, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
| | - I Barnaure
- Division of Neuroradiology, DISIM, Faculty of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland
| | - A M Korchi
- Division of Neuroradiology, DISIM, Faculty of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland
| | - M Scheffler
- Division of Radiology, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
| | - M I Vargas
- Division of Neuroradiology, DISIM, Faculty of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.
| |
Collapse
|
26
|
Prendki V, Huttner B, Marti C, Mamin A, Fubini PE, Meynet MP, Scheffler M, Montet X, Janssens JP, Reny JL, Kaiser L, Garin N, Stirnemann J. Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients: a prospective cohort study. Clin Microbiol Infect 2019; 25:1114-1119. [PMID: 30641227 PMCID: PMC7172172 DOI: 10.1016/j.cmi.2018.12.037] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Revised: 12/18/2018] [Accepted: 12/22/2018] [Indexed: 01/19/2023]
Abstract
OBJECTIVES We aimed to assess the accuracy of PCR detection of viruses and bacteria on nasopharyngeal and oropharyngeal swabs (NPS) for the diagnosis of pneumonia in elderly individuals. METHODS We included consecutive hospitalized elderly individuals suspected of having pneumonia. At inclusion, NPS were collected from all participants and tested by PCR for the presence of viral and bacterial respiratory pathogens (index test, defined as comprehensive molecular testing). Routine diagnostic tests (blood and sputum culture, urine antigen detection) were also performed. The reference standard was the presence of pneumonia on a low-dose CT scan as assessed by two independent expert radiologists. RESULTS The diagnosis of pneumonia was confirmed in 127 of 199 (64%) included patients (mean age 83 years, community-acquired pneumonia in 105 (83%)). A pathogen was identified by comprehensive molecular testing in 114 patients (57%) and by routine methods in 22 (11%). Comprehensive molecular testing was positive for viruses in 62 patients (31%) and for bacteria in 73 (37%). The sensitivity and specificity were 61% (95% CI 53%-69%) and 50% (95% CI 39%-61%) for comprehensive molecular testing, and 14% (95% CI 82%-21%) and 94% (95% CI 86%-98%) for routine testing, respectively. Positive likelihood ratio was 2.55 for routine methods and 1.23 for comprehensive molecular testing. CONCLUSION Comprehensive molecular testing of NPS increases the number of pathogens detected compared with routine methods, but results are poorly predictive of the presence of pneumonia. Hence, comprehensive molecular testing is unlikely to impact clinical decision-making (NCT02467192). CLINICAL TRIALS REGISTRATION NCT02467192.
Collapse
Affiliation(s)
- V Prendki
- ) Division of Internal Medicine and Rehabilitation, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland; ) Faculty of Medicine, University of Geneva, Switzerland.
| | - B Huttner
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Division of Infectious Diseases, Geneva University Hospitals, Switzerland
| | - C Marti
- ) Division of General Internal Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland
| | - A Mamin
- ) Division of Infectious Diseases, Geneva University Hospitals, Switzerland
| | - P E Fubini
- ) Division of Internal Medicine and Rehabilitation, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland; ) Division of General Internal Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland
| | - M P Meynet
- ) Division of Internal Medicine and Rehabilitation, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland
| | - M Scheffler
- ) Department of Radiology, Geneva University Hospitals, Switzerland
| | - X Montet
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Department of Radiology, Geneva University Hospitals, Switzerland
| | - J P Janssens
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Department of Pneumology, Geneva University Hospitals, Switzerland
| | - J L Reny
- ) Division of Internal Medicine and Rehabilitation, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland; ) Faculty of Medicine, University of Geneva, Switzerland; ) Division of General Internal Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland
| | - L Kaiser
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Division of Infectious Diseases, Geneva University Hospitals, Switzerland
| | - N Garin
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Division of General Internal Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland; ) Department of General Internal Medicine, Riviera Chablais Hospitals,Monthey, Switzerland
| | - J Stirnemann
- ) Faculty of Medicine, University of Geneva, Switzerland; ) Division of General Internal Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland
| |
Collapse
|
27
|
Chabbert-Buffet N, Marret H, Agostini A, Cardinale C, Hamdaoui N, Hassoun D, Jonville-Bera AP, Lambert M, Linet T, Pienkowski C, Plu-Bureau G, Pragout D, Robin G, Rousset-Jablonski C, Scheffler M, Vidal F, Vigoureux S, Hédon B. [Contraception: CNGOF Guidelines for Clinical Practice (Short Version)]. ACTA ACUST UNITED AC 2018; 46:760-776. [PMID: 30416023 DOI: 10.1016/j.gofs.2018.10.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Indexed: 12/26/2022]
Abstract
The French College of Obstetrics and Gynecology (CNGOF) releases its first global recommendations for clinical practice in contraception, to provide physicians with an updated synthesis of available data as a basis for their practice. The French Health Authority (HAS) methodology was used. Twelve practical issues were selected by the organizing committee and the task force members. The available literature was screened until December 2017, and allowed the release of evidence-based, graded recommendations. This synthesis is issued from 12 developed texts, previously reviewed by experts and physicians from public and private practices, with an experience in the contraceptive field. Male and female sterilization, as well as the use of hormonal treatments without contraceptive label were excluded from the field of this analysis. Specific practical recommendations on the management of contraception prescription, patient information including efficacy, risks, and benefits of the different contraception methods, follow up, intrauterine contraception, emergency contraception, local and natural methods, contraception in teenagers and after 40, contraception in vascular high-risk situations, and in case of cancer risk are provided. The short/mid-term future of contraception mostly relies on improving the use of currently available methods. This includes reinforced information for users and increased access to contraception for women, whatever the social and clinical context. That is the goal of these recommendations.
Collapse
Affiliation(s)
- N Chabbert-Buffet
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpitaux universitaires Est parisien, hôpital Tenon, Assistance publique des hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France; UMRS_938, Inserm Sorbonne université, 75012 Paris, France.
| | - H Marret
- Service de chirurgie pelvienne gynécologique et oncologique, centre hospitalier universitaire de Bretonneau, pôle de gynécologie-obstétrique, 2, boulevard Tonnellé, 37044 Tours cedex 1, France
| | - A Agostini
- Service de gynécologie-obstétrique, hôpital de la Conception, boulevard Baille, 13005 Marseille, France
| | - C Cardinale
- Service de gynécologie-obstétrique, hôpital de la Conception, boulevard Baille, 13005 Marseille, France
| | - N Hamdaoui
- Service de gynécologie-obstétrique, hôpital de la Conception, boulevard Baille, 13005 Marseille, France
| | - D Hassoun
- 38, rue Turenne, 75003 Paris, France
| | - A P Jonville-Bera
- Centre régional de pharmacovigilance, centre Val-de-Loire, CHRU de Tours, 37044 Tours cedex, France
| | - M Lambert
- Service de gynécologie et de médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie Raba-Léon, 33076 Bordeaux cedex, France
| | - T Linet
- Service de gynécologie-obstétrique, centre hospitalier de Loire-Vendée-Océan, 85302 Challans, France
| | - C Pienkowski
- Unité d'endocrinologie et de gynécologie médicale, TSA 70034, centre de référence de pathologies gynécologiques rares (PGR Toulouse), hôpital des Enfants, CHU de Toulouse, 31000 Toulouse, France
| | - G Plu-Bureau
- Unité de gynécologie endocrinienne, hôpital Port-Royal, 53, avenue de l'Observatoire, 75679 Paris, France; Université Paris Descartes, 75005 Paris, France; Inserm UMR 1153, Obstetrical, perinatal and paediatric epidemiology research team (Épopé), Centre for epidemiology and statistics Sorbonne Paris Cité (CRESS), 75005 Paris, France
| | - D Pragout
- Unité d'orthogénie, service de gynécologie-obstétrique, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - G Robin
- Centre d'assistance médicale à la procréation et de préservation de la fertilité, centre hospitalier universitaire de Lille, hôpital Jeanne de Flandre, 59000 Lille, France; EA 4308, gamétogenèse et qualité du gamète, centre hospitalier universitaire de Lille, 59000 Lille, France
| | - C Rousset-Jablonski
- Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Centre hospitalier de Lyon Sud, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France
| | - M Scheffler
- Service de gynécologie, CHU, 10, rue du Dr-Heydenreich, 54000 Nancy, France
| | - F Vidal
- CHU de Purpan, hôpital Paule-de-Viguier, pôle femme-mère-couple, 330, avenue Grande-Bretagne, 31059 Toulouse, France
| | - S Vigoureux
- Service de gynécologie-obstétrique, hôpital Bicêtre, Assistance publique des Hôpitaux de Paris (AP-HP), 94276 Le Kremlin-Bicêtre, France; Faculté de médecine Paris-Sud, université Paris-Sud, 94276 Le Kremlin-Bicêtre, France; U1018, Inserm, reproduction and child development, Centre for research in epidemiology and population health (CESP), 94805 Villejuif, France
| | - B Hédon
- Département de gynécologie-obstétrique, faculté de médecine université de Montpellier (France), centre hospitalier universitaire Arnaud-de-Villeneuve, 34000 Montpellier, France
| |
Collapse
|
28
|
Nees J, Schott S, Schafferer S, Müller U, Rom J, Tang Q, Koal T, Wolf B, Scheffler M, Marmé F, Sohn C, Schneeweiss A, Burwinkel B. Identification of a blood based metabolomic classifer for the detection of ovarian cancer – MeDOC. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Nees
- University Womens Clinic, Heidelberg, Deutschland
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
| | - S Schott
- University Womens Clinic, Heidelberg, Deutschland
| | - S Schafferer
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - U Müller
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - J Rom
- University Womens Clinic, Heidelberg, Deutschland
| | - Q Tang
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
- Molecular Epidemiology, C080, German Cancer Research Center, DKFZ, Heidelberg, Deutschland
| | - T Koal
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - B Wolf
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - M Scheffler
- Biocrates Life Sciences AG, Innsbruck, Österreich
| | - F Marmé
- National Center for Tumor Diseases, Heidelberg, Deutschland
| | - C Sohn
- University Womens Clinic, Heidelberg, Deutschland
| | - A Schneeweiss
- National Center for Tumor Diseases, Heidelberg, Deutschland
| | - B Burwinkel
- Molecular Biology of Breast Cancer, University Womens Clinic, Heidelberg, Deutschland
- Molecular Epidemiology, C080, German Cancer Research Center, DKFZ, Heidelberg, Deutschland
| |
Collapse
|
29
|
Ohlmann C, Roger Z, Rüssel C, Hellmis E, Suttmann H, Janssen M, Hübner A, Dahm J, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J. Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Salazar C, Baumann D, Hänke T, Scheffler M, Kühne T, Kaiser M, Voigtländer R, Lindackers D, Büchner B, Hess C. An ultra-high vacuum scanning tunneling microscope operating at sub-Kelvin temperatures and high magnetic fields for spin-resolved measurements. Rev Sci Instrum 2018; 89:065104. [PMID: 29960518 DOI: 10.1063/1.5027782] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
We present the construction and performance of an ultra-low-temperature scanning tunneling microscope (STM), working in ultra-high vacuum (UHV) conditions and in high magnetic fields up to 9 T. The cryogenic environment of the STM is generated by a single-shot 3He magnet cryostat in combination with a 4He dewar system. At a base temperature (300 mK), the cryostat has an operation time of approximately 80 h. The special design of the microscope allows the transfer of the STM head from the cryostat to a UHV chamber system, where samples and STM tips can be easily exchanged. The UHV chambers are equipped with specific surface science treatment tools for the functionalization of samples and tips, including high-temperature treatments and thin film deposition. This, in particular, enables spin-resolved tunneling measurements. We present test measurements using well-known samples and tips based on superconductors and metallic materials such as LiFeAs, Nb, Fe, and W. The measurements demonstrate the outstanding performance of the STM with high spatial and energy resolution as well as the spin-resolved capability.
Collapse
Affiliation(s)
- C Salazar
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - D Baumann
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - T Hänke
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - M Scheffler
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - T Kühne
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - M Kaiser
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - R Voigtländer
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - D Lindackers
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - B Büchner
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| | - C Hess
- Leibniz Institute for Solid State and Materials Research, IFW-Dresden, Helmholtzstraße 20, 01069 Dresden, Germany
| |
Collapse
|
31
|
Kron A, Riedel R, Michels S, Fassunke J, Merkelbach-Bruse S, Scheffler M, Nogova L, Fischer R, Ueckeroth F, Abdulla D, Kron F, Pauli B, Kaminsky B, Braess J, Graeven U, Grohe C, Krueger S, Büttner R, Wolf J. Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Riedel R, Kron A, Michels S, Fassunke J, Scheffler M, Fischer R, Nogova L, Abdulla D, Heydt C, Ueckeroth F, Pauli B, Serke M, Krueger S, Grohe C, Sebastian M, Koschel D, Kambartel KO, Zander T, Büttner R, Wolf J. Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Prendki V, Scheffler M, Garin N, Carballo S, Serratrice C, Marti C, Roux X, Serratrice J, Montet X, Reny J, Stirnemann J. Intérêt du scanner thoracique low-dose dans le diagnostic de la pneumonie du sujet âgé. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Kambartel K, Eggert J, Kopeika U, Liebisch P, Mlynek-Kersjes ML, Rösel C, Scheffler M, Yildirim A, Krbek T, Wolf J, Büttner R, Voshaar T. Erfolgreiche Therapie mit Afatinib und Crizotinib bei einer cMET-Amplifikation als Ursache einer sekundären EGFR-Resistenz. Pneumologie 2017. [DOI: 10.1055/s-0037-1598336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- K Kambartel
- Lungenzentrum, Pneumologie, Krankenhaus Bethanien Moers
| | | | - U Kopeika
- Lungenzentrum, Pneumologie, Krankenhaus Bethanien Moers
| | | | | | - C Rösel
- Thoraxchirurgie, Krankenhaus Bethanien Moers
| | - M Scheffler
- Klinik I für Innere Medizin I, Centrum für Integrierte Onkologie (Cio), Universitätsklinikum Köln
| | - A Yildirim
- Lungenzentrum, Pneumologie, Krankenhaus Bethanien Moers
| | - T Krbek
- Thoraxchirurgie, Krankenhaus Bethanien Moers
| | - J Wolf
- Klinik I für Innere Medizin I, Centrum für Integrierte Onkologie (Cio), Universitätsklinikum Köln
| | - R Büttner
- Zentrum für Pathologie, Universitätsklinik Köln
| | - T Voshaar
- Lungenzentrum, Pneumologie, Krankenhaus Bethanien Moers
| |
Collapse
|
35
|
Koleczko S, Schäpers C, Scheffler M, Ihle M, Kostenko A, Michels S, Fischer R, Nogova L, Brandes V, Abdulla D, Ueckeroth F, Thurat M, Frank R, Eisert A, Bitter E, Wömpner C, Gogl L, Merkelbach-Bruse S, Büttner R, Wolf J. A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Nicholson EG, Schlegel C, Garofalo RP, Mehta R, Scheffler M, Mei M, Piedra PA. Robust Cytokine and Chemokine Response in Nasopharyngeal Secretions: Association With Decreased Severity in Children With Physician Diagnosed Bronchiolitis. J Infect Dis 2016; 214:649-55. [PMID: 27190183 PMCID: PMC4957440 DOI: 10.1093/infdis/jiw191] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 05/03/2016] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Bronchiolitis causes substantial disease in young children. Previous findings had indicated that a robust innate immune response was not associated with a poor clinical outcome in bronchiolitis. This study tested the hypothesis that increased concentrations of cytokines and chemokines in nasal wash specimens were associated with decreased severity in bronchiolitis. METHODS Children <24 months old who presented to the emergency department with signs and symptoms of bronchiolitis were eligible for enrollment. Nasal wash specimens were analyzed for viral pathogens and cytokine/chemokine concentrations. These results were evaluated with regard to disposition. RESULTS One hundred eleven children with bronchiolitis were enrolled. A viral pathogen was identified in 91.9% of patients (respiratory syncytial virus in 51.4%, human rhinovirus in 11.7%). Higher levels of cytokines and chemokines (interferon [IFN] γ; interleukin [IL] 4, 15, and 17; CXCL10; and eotaxin) were significantly associated with a decreased risk of hospitalization. IL-17, IL-4, IFN-γ, and IFN-γ-inducible protein 10 (CXCL10 or IP-10) remained statistically significant in the multivariate analyses. CONCLUSIONS The cytokines and chemokines significantly associated with decreased bronchiolitis severity are classified in a wide range of functional groups (T-helper 1 and 2, regulatory, and chemoattractant). The involvement of these functional groups suggest that a broadly overlapping cytokine/chemokine response is required for control of virus-mediated respiratory disease in young children.
Collapse
Affiliation(s)
| | | | | | - Reena Mehta
- Allergy & Asthma Specialists, Saddle River, New Jersey
| | - Margaret Scheffler
- Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island
| | - Minghua Mei
- Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston
| | - Pedro A Piedra
- Department of Pediatric Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston
| |
Collapse
|
37
|
Ziemssen F, Hufenbach U, Wiedon A, Scheffler M, Bertelmann T. [Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study]. Klin Monbl Augenheilkd 2016; 233:1367-1377. [PMID: 27454304 DOI: 10.1055/s-0042-100472] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Background: The main cause of blindness in the elderly in Germany is neovascular age-related macular degeneration (nAMD). In the non-interventional OCEAN study, data were prospectively collected on the routine clinical care of patients treated with the drug ranibizumab. Patients: As part of an interim analysis within the ongoing study (NCT02194803), stratification was performed by the 17 regions of the German associations of panel physicians and by areas of different population density. Only data were analysed for patients for whom the first treatment with ranibizumab was documented. Results: A total of 5,606 patients were documented. The present manuscript reviews 2,658 treatment-naive patients with nAMD, documented by 324 ophthalmologists. Most patients receiving an intravitreal injection were female (60 %). The average patient was aged 77.7 ± 8.2 years at study start. The great majority of patients had statutory health insurance (91 %). At baseline, fluorescein angiography (FLA) was performed for 72 % of patients, while optical coherence tomography (OCT) was carried out for 76 %. A combination of both was performed for 54 % of patients, varying regionally from 26 % (Saxony-Anhalt) to 100 % (Berlin). The average waiting time between the first examination and the first injection was 20.0 ± 18.5 days. With different statistical models (ANOVA adjusted, with/without interactions), significant effects on treatment delay were found for district type (population density), federal state and type of specialist. Conclusion: No major regional differences were observed in the demographic characteristics of the patient population. The main regional disparities in the care of nAMD patients were in the application of diagnostic methods and the waiting times between the first examination and the first drug administration. The regional variations in treatment delays could clearly influence the risk of worse functional outcome.
Collapse
Affiliation(s)
- F Ziemssen
- Department für Augenheilkunde, Eberhard-Karls-Universität Tübingen
| | | | - A Wiedon
- Medical Advisor, Novartis Pharma, Nürnberg
| | | | - T Bertelmann
- Universitätsaugenklinik, Philipps-Universität Marburg
| |
Collapse
|
38
|
Clesse C, Lighezzolo-Alnot J, Hamlin S, De Lavergne S, Scheffler M. [The practice of episiotomy in France 10 years after the recommendations of CNGOF: What inventory?]. ACTA ACUST UNITED AC 2016; 44:232-8. [PMID: 26997462 DOI: 10.1016/j.gyobfe.2016.02.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2015] [Accepted: 02/09/2016] [Indexed: 12/14/2022]
Abstract
Since its creation, the practice of episiotomy has evolved, being influenced by several factors. Various stances on its use were stated, until the eventual reduction of this practice, as suggested by numerous practical guides. In 2005, the National College of Obstetricians and Gynecologists in France published its French Guidelines for Clinical practice in this area. Today, it seems appropriate to focus on the evolution of the use of episiotomy, ten years after the publication of these recommendations. The authors propose a literature review, browsing through all the available epidemiological data in France related to episiotomy, recording all national statistics and some local trends, as there are regional specificities. This review allows to follow the overall evolution of the practice of episiotomy in France between 1981 and 2014, and to identify territorial disparities. Finally, in the specific context of the practice of episiotomy in French gynecological and obstetrics field, the authors conclude it by considering the possible evolution of this surgical practice, as well as, the Clinical Practice Recommendations related to it.
Collapse
Affiliation(s)
- C Clesse
- Laboratoire interpsy (EA4432), université de Lorraine, Nancy 2, 3, place Godeffroy-de-Bouillon, 54000 Nancy, France; Centre hospitalier de Jury-les-Metz, route d'Ars-Laquenexy, BP 75088, 57073 Jury-Les-Metz cedex 03, France.
| | - J Lighezzolo-Alnot
- Laboratoire interpsy (EA4432), université de Lorraine, Nancy 2, 3, place Godeffroy-de-Bouillon, 54000 Nancy, France
| | - S Hamlin
- Polyclinique Majorelle, 1240, avenue Raymond-Pinchard, 54100 Nancy, France
| | - S De Lavergne
- Polyclinique Majorelle, 1240, avenue Raymond-Pinchard, 54100 Nancy, France
| | - M Scheffler
- Polyclinique Majorelle, 1240, avenue Raymond-Pinchard, 54100 Nancy, France; Cabinet de gynécologie médicale et obstétrique, 21, avenue Foch, 54000 Nancy, France
| |
Collapse
|
39
|
Gogl L, Scheffler M, Ihle M, Michels S, Fischer R, Serke M, Gerigk U, Wömpner C, Krüger S, Kaminsky B, Schulte W, Höffken G, Merkelbach-Bruse S, Büttner R, Wolf J. 3131 Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31772-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Ziemssen F, Bertelmann T, Hufenbach U, Scheffler M, Liakopoulos S, Schmitz-Valckenberg S. Verzögerung des Behandlungsbeginns um mehr als 2 Wochen. Ophthalmologe 2015. [DOI: 10.1007/s00347-015-0099-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
41
|
Frank R, Scheffler M, Michels S, König K, Merkelbach-Bruse S, Serke M, Ko Y, Gerigk U, Geist T, Heukamp L, Büttner R, Wolf J. Occurrence and Characteristics of Keap1-Mutations in Patients with Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Michels S, Schultheis A, Scheffler M, Rosner T, Merkelbach-Bruse S, Heukamp L, Engel-Riedel W, Serke M, Krüger S, Benedikter J, Gerigk U, Schulte W, Draube A, Ko Y, Büttner R, Wolf J. Ret Translocation in Adenocarcinoma of the Lung. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Eisert A, Scheffler M, Michels S, Schultheis A, König K, Merkelbach-Bruse S, Serke M, Ko Y, Gerigk U, Geist T, Heukamp L, Büttner R, Wolf J. Genetic Variability and Clinical Presentation of Patients with Non-Small Cell Lung Cancer (Nsclc) Harboring Met-Amplifications. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Nogova L, Mattonet C, Scheffler M, Michels S, Bos M, Heukamp L, Schildhaus H, Fuhr U, Eberhardt W, Reis H, Wiesweg M, Schmid K, Schoch G, Serke M, Ko Y, Schuler M, Büttner R, Wolf J. Try - a Phase Ii Study to Evaluate Safety and Efficacy of Combined Trastuzumab and the Hsp90 Inhibitor Auy922 in Advanced Non-Small-Cell Lung Cancer (Nsclc) with Her2 Overexpression or Amplification or Mutation. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Mehta R, Scheffler M, Tapia L, Aideyan L, Patel KD, Jewell AM, Avadhanula V, Mei M, Garofalo RP, Piedra PA. Lactate dehydrogenase and caspase activity in nasopharyngeal secretions are predictors of bronchiolitis severity. Influenza Other Respir Viruses 2014; 8:617-25. [PMID: 25132512 PMCID: PMC4262276 DOI: 10.1111/irv.12276] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/23/2014] [Indexed: 01/19/2023] Open
Abstract
Background Bronchiolitis is the leading cause of hospitalization in infants. Biomarkers of disease severity might help in clinical management. Objective To determine the clinical predictiveness of NW-LDH, NW-caspase 3/7, and NW-LDH/NW-caspase 3/7 ratio in bronchiolitis. Methods Previously healthy children less than 24 months of age with bronchiolitis were recruited from the Texas Children's emergency room and intensive care unit from October 2010 to April 2011. Demographic, clinical information, and NW samples were obtained at enrollment. NW samples were analyzed for respiratory viruses, caspase 3/7, and LDH. Results A viral pathogen was detected in 91·6% of 131 children, with the most common being respiratory syncytial virus and human rhinovirus. A single infection was found in 61·8% of subjects and co-infection in 29·8%. Children admitted to ICU had significantly higher NW-LDH than children sent home from the ER or admitted to the general floor (P = 0·02). Children infected with RSV had the highest NW-LDH concentration (P = 0·03) compared with other viral infections. NW-LDH and NW-caspase were significantly correlated (r = 0·77, P < 0·0001). The univariate models showed NW-LDH and NW-LDH/NW- caspase 3/7 ratio were directly associated with hospitalization. Mutivariate regression analyses suggested a complex interaction between the biomarkers, demographics, and disposition. Conclusions NW-LDH, NW-caspase 3/7 and NW-LDH/NW-caspase 3/7 ratio and their interactions with demographic factors are predictive of bronchiolitis severity and can help distinguish children requiring ICU-level care from those admitted to the general floor, or discharged home from the emergency center.
Collapse
Affiliation(s)
- Reena Mehta
- Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Zywietz T, Neugebauer J, Scheffler M, Northrup J, Van de Walle CG. Surface Structures, Surfactants and Diffusion at Cubic and Wurtzite GaN. ACTA ACUST UNITED AC 2014. [DOI: 10.1557/s1092578300000983] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Clean and As covered zinc-blende and wurtzite GaN surfaces have been investigated employing density-functional theory calculations. For clean GaN surfaces our calculations indicate the stability of several novel surface structures that are very different from those found on traditional III-V semiconductors. Adding impurities commonly present in significant concentrations during growth strongly modifies surface reconstructions and energies. In particular, we find that arsenic has a low solubility and significantly stabilizes the cubic GaN (001) surface making it interesting as a potential surfactant. Finally, we have studied the diffusion of Ga and N adatoms on both the equilibrium and non-equilibrium surfaces. Our calculations reveal a very different diffusivity for Ga and N adatoms: While Ga adatoms are very mobile at typical growth temperatures, the diffusion of N adatoms is slower by several orders of magnitude. These results give insight into the fundamental growth mechanisms and allow conclusions concerning optimum growth conditions.
Collapse
|
47
|
Scheffler M, Drawe H, Henglein A. Die Reaktionen des weißen Phosphors mit Dimethyldisulfid unter γ-Bestrahlung. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-1968-0705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Trimethylthiophosphite and red phosphorus are formed when solutions of white phosphorus in dimethyldisulfide are exposed to γ-radiation. The red phosphorus has a high content of CH3S groups. It is very reactive and can be converted into trimethylthiophosphite upon further irradiation in dimethyldisulfide suspension. Both the formation of red phosphorus from white phosphorus and the formation of trimethylthiophosphite from red phosphorus are chain processes. The radiation chemical yields are of the order of several 100 molecules/100 eV at room temperature.
Collapse
Affiliation(s)
- M. Scheffler
- Hahn-Meitner-Institut für Kernforschung, 1 Berlin-Wannsee
| | - H. Drawe
- Hahn-Meitner-Institut für Kernforschung, 1 Berlin-Wannsee
| | - A. Henglein
- Hahn-Meitner-Institut für Kernforschung, 1 Berlin-Wannsee
| |
Collapse
|
48
|
Scheffler M, Henglein A. Notizen: Über Kettenreaktionen bei der Auflösung von reaktivem Phosphor in Dimethyldisulfid unter Einfluß von γ-Strahlung. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-1970-0126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M. Scheffler
- Hahn-Meitner-Institut für Kernforschung Berlin, Sektor Strahlenchemie
| | - A. Henglein
- Hahn-Meitner-Institut für Kernforschung Berlin, Sektor Strahlenchemie
| |
Collapse
|
49
|
Chabbert-Buffet N, Guigues B, Trillot N, Biron C, Morange P, Pernod G, Scheffler M, Brugere S, Hedon B. [DVT and combined oral contraceptives: update of the pluridisciplinary CNGOF-FNCGM-GEHT-SFMV group]. J Gynecol Obstet Hum Reprod 2013; 42:309-315. [PMID: 23642503 DOI: 10.1016/j.jgyn.2013.03.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Revised: 03/25/2013] [Accepted: 03/26/2013] [Indexed: 06/02/2023]
Abstract
Thrombotic risk among combined oral contraceptives (COC) users has recently been debated following a court action initiated by a patient. Recent epidemiological data, as well as accumulating biological data underlying these data, have led French Health authorities to modify COC prescription and reimbursement modalities. A short synthesis is proposed by a multidisciplinary group of experts from four French societies (CGOF, FNCGM, GHT, and SFMV).
Collapse
Affiliation(s)
- N Chabbert-Buffet
- Collège national des gynécologues-obstétriciens français (CNGOF), 91, boulevard de Sébastopol, 75002 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013; 81:142-3. [PMID: 23558310 DOI: 10.1016/j.lungcan.2013.02.018] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 02/19/2013] [Indexed: 11/30/2022]
Abstract
A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy (carboplatin, gemcitabine, docetaxel, pemetrexed) and targeted agents (erlotinib, cetuximab, sunitinib). Comprehensive molecular diagnostics (EGFR-, ALK-, RAS-, BRAF-, PIK3CA-, HER2- and DDR2-aberrations) were performed and failed initially to detect any driver mutation. While the patient suffered from rapid deterioration of her general condition, in particular from progressive dyspnea due to lung metastases, we implemented screening for RET- and ROS1 translocations into our molecular diagnostic program based on recent reports of these new molecular subgroups in lung adenocarcinoma. On retesting the patient's tumor sample was found to harbor a ROS1-translocation. The patient was subsequently treated with crizotinib and experienced a pronounced clinical improvement corresponding to a complete metabolic response in (18)F-FDG-PET and a good and confirmed partial response in CT (RECIST 1.1). Our case exemplifies the need for rapid implementation of newly discovered rare genetic lung cancer subtypes in routine molecular diagnostics.
Collapse
Affiliation(s)
- M Bos
- Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|